8-K: Teva Pharmaceutical Reports Strong Q3 2024 Results, Raises Full-Year Outlook

Teva Pharmaceutical Industries Ltd. announced strong third-quarter 2024 financial results, driven by generics performance and innovative portfolio growth, leading to an increased full-year outlook.

Summary

• Teva's Q3 2024 revenues reached $4.3 billion, a 13% increase in U.S. dollars and 15% in local currency compared to Q3 2023.
• The company's generics business grew across all regions, with a 30% increase in the U.S., 8% in Europe, and 13% in International Markets, all in local currency terms.
• AUSTEDO U.S. revenues were $435 million, a 28% increase from Q3 2023, and the 2024 revenue outlook is reaffirmed at approximately $1.6 billion.
• AJOVY global revenues reached $137 million, a 21% increase in local currency terms compared to Q3 2023.
• UZEDY U.S. revenues were $35 million, and the 2024 revenue outlook was raised from approximately $80 million to approximately $100 million.
• Teva's biosimilar candidate to Prolia has been accepted for review by the U.S. FDA and the European Medicines Agency.
• The company intends to divest Teva api, with completion targeted for the first half of 2025.
• Teva's full-year 2024 business outlook has been raised to revenues of $16.1 $16.5 billion, operating income of $4.2-$4.5 billion, adjusted EBITDA of $4.7 $5.0 billion, and non-GAAP diluted EPS of $2.40$2.50.
• The company generated $693 million in cash flow from operating activities and $922 million in free cash flow during the third quarter of 2024.

Sentiment

Score: 8

Explanation: The document presents a strong positive sentiment due to the company's revenue growth, raised outlook, and successful execution of its growth strategy. While there are some negative aspects, such as the GAAP loss and certain product declines, the overall tone is optimistic and forward-looking.

Positives

• Teva achieved its seventh consecutive quarter of growth, with global revenues reaching $4.3 billion.
• The company's innovative portfolio and generics business drove strong performance in Q3 2024.
• The Pivot to Growth strategy is being successfully executed, with the company delivering on its ambitious targets.
• The company's early and late-stage innovative pipeline continues to progress.
• Teva's full-year 2024 business outlook has been raised, including on revenues, Adjusted EBITDA, and Non-GAAP EPS.
• The company generated strong cash flow from operating activities and free cash flow in Q3 2024.
• The company's debt decreased to $18,980 million as of September 30, 2024, compared to $19,833 million as of December 31, 2023.

Negatives

• Teva reported a GAAP loss per share of $0.39 for Q3 2024.
• The company experienced an operating loss of $51 million in Q3 2024, compared to an operating income of $344 million in Q3 2023, mainly due to a goodwill impairment charge and higher legal settlements.
• Exchange rate movements negatively impacted revenues by $88 million and operating loss by $57 million.
• COPAXONE revenues in the U.S. decreased by 30% due to market share erosion and competition.
• BENDEKA and TREANDA combined revenues in the U.S. decreased by 28% due to competition.
• The company recognized a tax expense of $69 million on a pre-tax loss of $324 million.
• The company's tax rate for the third quarter of 2024 was mainly impacted by impairment charges with no corresponding tax effects, an adjustment to Teva's corporate tax rate in Israel on losses related to non-qualified tax incentive activities in Israel, legal expenses with no corresponding tax effect related to the fine issued by the European Commission in connection with its antitrust investigation into COPAXONE, and recording of valuation allowance with respect to certain carry over credits outside of Israel.

Risks

• The company faces risks related to competition in the marketplace, particularly for its generic products and innovative medicines.
• Teva's substantial indebtedness may limit its ability to incur additional debt or make new investments.
• The company is subject to extensive pharmaceutical regulation, which could lead to costs and delays.
• Teva faces compliance, regulatory, and litigation risks, including potential liability for intellectual property infringement and product liability claims.
• The company is exposed to currency fluctuations and restrictions, as well as credit risks.
• The ongoing conflict between Russia and Ukraine and the state of war declared in Israel could disrupt operations and facilities.
• The company is subject to scrutiny from competition and pricing authorities around the world.
• The company is subject to potential impairments of its long-lived assets.

Future Outlook

Teva has raised its full-year 2024 business outlook, projecting revenues of $16.1 $16.5 billion, operating income of $4.2-$4.5 billion, adjusted EBITDA of $4.7 $5.0 billion, and non-GAAP diluted EPS of $2.40$2.50. The company also expects UZEDY revenues of approximately $100 million and COPAXONE revenues of approximately $500 million.

Management Comments

• Mr. Richard Francis, Teva's President and CEO, said, 'The third quarter of 2024 marks our seventh consecutive quarter of growth, with global revenues reaching $4.3 billion, an increase of 15% in local currency terms compared to the third quarter of 2023.'
• Mr. Francis continued, 'Our innovative portfolio and generics business drove strong performance in the third quarter of 2024, reflecting the successful execution of our Pivot to Growth Strategy.'
• Mr. Francis also stated, 'I am confident that with our newly accelerated innovative pipeline, both earlyand late-stage, we are well-positioned to provide meaningful access to medicines for patients who need them, while also delivering continued growth for our shareholders.'

Industry Context

Teva's strong Q3 results and raised outlook reflect a positive trend in the pharmaceutical industry, particularly in the generics and innovative drug sectors. The company's focus on its Pivot to Growth strategy, including the development of biosimilars and innovative medicines, aligns with broader industry trends towards expanding treatment options and addressing unmet medical needs. The divestiture of the API business also reflects a strategic shift towards core growth areas.

Comparison to Industry Standards

• Teva's 15% revenue growth in local currency terms is strong compared to many large pharmaceutical companies, although direct comparisons are difficult due to varying product portfolios and geographic focuses.
• The 30% growth in US generics revenue is particularly notable, indicating strong market penetration and execution in this key segment.
• The 28% growth in AUSTEDO revenue is impressive, suggesting successful commercialization and market adoption of this innovative product.
• The increase in UZEDY revenue and the raised outlook indicate a successful launch and growing market acceptance, although it is still early in its lifecycle.
• The company's adjusted EBITDA margin of 28% is competitive with industry peers, although it is important to note that this is a non-GAAP metric.
• The company's free cash flow generation of $922 million in Q3 is a positive sign of financial health and operational efficiency.
• Compared to companies like Mylan (now Viatris) and Sandoz, Teva's focus on both generics and innovative products provides a diversified approach to growth.
• The divestiture of the API business is similar to moves by other large pharmaceutical companies to streamline operations and focus on core competencies.

Legal Proceedings

• The company recorded a provision of $350 million in connection with a decision by the European Commission in its antitrust investigation into COPAXONE, which Teva intends to appeal.
• The company updated the estimated settlement provision of $121 million for the opioid cases, mainly related to the settlement agreement with the city of Baltimore and the effect of the passage of time on the net present value of the discounted payments.

Stakeholder Impact

• Shareholders will benefit from the increased revenue and raised financial outlook.
• Patients will have access to new and innovative medicines through Teva's pipeline.
• Employees will be impacted by the company's strategic shifts and restructuring efforts.
• Customers will benefit from the company's continued focus on quality and innovation.
• Suppliers will be impacted by the company's optimization of its manufacturing footprint.
• Creditors will be impacted by the company's debt reduction efforts.

Next Steps

• Teva will continue to execute its Pivot to Growth strategy.
• The company will focus on delivering on its growth engines, including AUSTEDO, AJOVY, UZEDY, and its late-stage pipeline of biosimilars.
• Teva will continue to step up innovation through its late-stage innovative pipeline assets and build its early-stage pipeline.
• The company will sustain its generics medicines business with a global commercial footprint.
• Teva will optimize its portfolio and global manufacturing footprint to enable strategic capital deployment.
• The company intends to complete the divestiture of its API business in the first half of 2025.
• Teva will continue to progress its early and late-stage innovative pipeline, with duvakitug (Anti-TL1A) top-line results expected in Q4 2024.

Key Dates

Keywords

Pharmaceuticals, Generics, AUSTEDO, AJOVY, UZEDY, Biosimilars, Financial Results, Revenue, EBITDA, EPS, Teva, Pivot to Growth Strategy